{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:21:16Z","timestamp":1793647276909,"version":"4.5.1"},"reference-count":88,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1016\/j.blre.2007.11.001","type":"journal-article","created":{"date-parts":[[2008,1,17]],"date-time":"2008-01-17T12:39:57Z","timestamp":1200573597000},"page":"107-116","source":"Crossref","is-referenced-by-count":29,"title":["Aspirin and other antiplatelet drugs in the prevention of venous thromboembolism"],"prefix":"10.1016","volume":"22","author":[{"given":"Henry G","family":"Watson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen Lin","family":"Chee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2007.11.001_bib1","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1056\/NEJM199412153312401","article-title":"A prospective study of venous thromboembolism after major trauma","volume":"331","author":"Geerts","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2007.11.001_bib2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF02015324","article-title":"Surveillance venous scans for deep venous thrombosis in multiple trauma patients","volume":"9","author":"Meyer","year":"1995","journal-title":"Ann Vasc Surg"},{"key":"10.1016\/j.blre.2007.11.001_bib3","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/00005373-200203000-00007","article-title":"The role of surveillance duplex scanning in preventing venous thromboembolism in trauma patients","volume":"52","author":"Cipolle","year":"2002","journal-title":"J Trauma"},{"key":"10.1016\/j.blre.2007.11.001_bib4","doi-asserted-by":"crossref","first-page":"338S","DOI":"10.1378\/chest.126.3_suppl.338S","article-title":"Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"Geerts","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.blre.2007.11.001_bib5","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1160\/TH07-01-0055","article-title":"Rivaroxaban for thromboprophylaxis after orthopaedic surgery: Pooled analysis of two studies","volume":"97","author":"Fisher","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2007.11.001_bib6","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(02)08648-8","article-title":"Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial","volume":"359","author":"Turpie","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2007.11.001_bib7","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0140-6736(02)08652-X","article-title":"Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison","volume":"359","author":"Lassen","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2007.11.001_bib8","doi-asserted-by":"crossref","unstructured":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71\u201386.","DOI":"10.1136\/bmj.324.7329.71"},{"key":"10.1016\/j.blre.2007.11.001_bib9","doi-asserted-by":"crossref","unstructured":"Sandercock P, Gubitz G, Foley P et al. Antiplatelet therapy for acute ischaemic stroke. Cochrane Database Syst Rev. 2003;CD000029.","DOI":"10.1002\/14651858.CD000029"},{"key":"10.1016\/j.blre.2007.11.001_bib10","doi-asserted-by":"crossref","unstructured":"Prevention of fatal postoperative pulmonary embolism by low doses of heparin. An international multicentre trial. Lancet. 1975; 2:45\u201351.","DOI":"10.1016\/S0140-6736(75)90494-8"},{"key":"10.1016\/j.blre.2007.11.001_bib11","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1136\/bmj.4.5991.257","article-title":"Low-dose heparin prophylaxis against fatal pulmonary embolism","volume":"4","author":"Sagar","year":"1975","journal-title":"Br Med J"},{"key":"10.1016\/j.blre.2007.11.001_bib12","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1056\/NEJM198805053181805","article-title":"Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery","volume":"318","author":"Collins","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2007.11.001_bib13","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1055\/s-0038-1649258","article-title":"Early venous thrombosis: A scanning electron microscopic study","volume":"37","author":"Day","year":"1977","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2007.11.001_bib14","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/jcp.27.7.517","article-title":"The structure and growth of valve-pocket thrombi in femoral veins","volume":"27","author":"Sevitt","year":"1974","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.blre.2007.11.001_bib15","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.thromres.2006.04.011","article-title":"Quantification of platelet composition in experimental venous thrombosis by real-time polymerase chain reaction","volume":"119","author":"Wang","year":"2007","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2007.11.001_bib16","first-page":"1109","article-title":"Effect of thromboxane receptor antagonists on venous thrombosis in rats","volume":"248","author":"Schumacher","year":"1989","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.blre.2007.11.001_bib17","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/0049-3848(87)90228-3","article-title":"Thromboxane and prostacyclin formation in patients with deep vein thrombosis","volume":"45","author":"Vesterqvist","year":"1987","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2007.11.001_bib18","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1378\/chest.85.3.329","article-title":"Urinary excretion of thromboxane B2 in patients with venous thromboembolic disease","volume":"85","author":"Klotz","year":"1984","journal-title":"Chest"},{"key":"10.1016\/j.blre.2007.11.001_bib19","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jvs.2005.04.045","article-title":"Decreased venous thrombosis with an oral inhibitor of P selectin","volume":"42","author":"Myers","year":"2005","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.blre.2007.11.001_bib20","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1160\/TH06-11-0658","article-title":"Resolution of venous thrombosis using a novel oral small-molecule inhibitor of P-selectin (PSI-697) without anticoagulation","volume":"97","author":"Myers","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2007.11.001_bib21","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1111\/j.1538-7836.2006.02138.x","article-title":"Venous thromboembolism and atherosclerosis: common denominators or different diseases?","volume":"4","author":"Agnelli","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2007.11.001_bib22","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1056\/NEJMoa020496","article-title":"Warfarin, aspirin, or both after myocardial infarction","volume":"347","author":"Hurlen","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2007.11.001_bib23","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1538-7836.2006.01795.x","article-title":"Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months","volume":"4","author":"Schulman","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2007.11.001_bib24","doi-asserted-by":"crossref","unstructured":"Effect of aspirin on postoperative venous thrombosis. Report of the Steering Committee of a trial sponsored by the Medical Research Council. Lancet. 1972;2:441\u2013445.","DOI":"10.1016\/S0140-6736(72)91849-1"},{"key":"10.1016\/j.blre.2007.11.001_bib25","first-page":"227","article-title":"Prevention of venous thromboembolism in general surgical patients","volume":"208","author":"Clagett","year":"1988","journal-title":"Results of meta-analysis. Ann Surg"},{"key":"10.1016\/j.blre.2007.11.001_bib26","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1001\/jama.271.22.1780","article-title":"A meta-analysis of methods to prevent venous thromboembolism following total hip replacement","volume":"271","author":"Imperiale","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.blre.2007.11.001_bib27","doi-asserted-by":"crossref","unstructured":"Collaborative overview of randomised trials of antiplatelet therapy\u2013III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists\u2019 Collaboration. BMJ. 1994;308:235\u201346.","DOI":"10.1136\/bmj.308.6923.235"},{"key":"10.1016\/j.blre.2007.11.001_bib28","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1136\/bmj.309.6963.1213","article-title":"Antiplatelet treatment for thromboprophylaxis: a step forward or backwards?","volume":"309","author":"Cohen","year":"1994","journal-title":"BMJ"},{"key":"10.1016\/j.blre.2007.11.001_bib29","doi-asserted-by":"crossref","unstructured":"Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet. 2000;355:1295\u20131302.","DOI":"10.1016\/S0140-6736(00)02110-3"},{"key":"10.1016\/j.blre.2007.11.001_bib30","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/01.CIR.93.1.80","article-title":"Low-molecular-weight heparinoid orgaran is more effective than aspirin in the prevention of venous thromboembolism after surgery for hip fracture","volume":"93","author":"Gent","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.blre.2007.11.001_bib31","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00003086-199603000-00031","article-title":"Aspirin and warfarin for thromboembolic disease after total joint arthroplasty","author":"Lotke","year":"1996","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.blre.2007.11.001_bib32","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s001130050231","article-title":"[Prospective randomized pilot study of ambulatory prevention of thromboembolism. 2 times 500 mg aspirin (ASS) vs. clivarin 1750 (NMH)]","volume":"101","author":"Gehling","year":"1998","journal-title":"Unfallchirurg"},{"key":"10.1016\/j.blre.2007.11.001_bib33","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1302\/0301-620X.82B6.9869","article-title":"Meta-analysis of thromboembolic prophylaxis after total knee arthroplasty","volume":"82","author":"Westrich","year":"2000","journal-title":"J Bone Joint Surg Br"},{"key":"10.1016\/j.blre.2007.11.001_bib34","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.arth.2006.05.017","article-title":"VenaFlow plus Lovenox vs VenaFlow plus aspirin for thromboembolic disease prophylaxis in total knee arthroplasty","volume":"21","author":"Westrich","year":"2006","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.blre.2007.11.001_bib35","doi-asserted-by":"crossref","first-page":"826","DOI":"10.2106\/00004623-199606000-00004","article-title":"Prophylaxis against deep venous thrombosis after total knee arthroplasty. Pneumatic plantar compression and aspirin compared with aspirin alone","volume":"78","author":"Westrich","year":"1996","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.blre.2007.11.001_bib36","doi-asserted-by":"crossref","unstructured":"CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet. 1997;349:1641\u201349.","DOI":"10.1016\/S0140-6736(97)04010-5"},{"key":"10.1016\/j.blre.2007.11.001_bib37","doi-asserted-by":"crossref","unstructured":"The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet. 1997;349:1569\u201381.","DOI":"10.1016\/S0140-6736(97)04011-7"},{"key":"10.1016\/j.blre.2007.11.001_bib38","unstructured":"Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre Acute Stroke Trial\u2013Italy (MAST-I) Group. Lancet. 1995;346:1509\u201314."},{"key":"10.1016\/j.blre.2007.11.001_bib39","unstructured":"Utsumi. Evaluation of utility of ticlopidine, an antiplatelet agent for acute cerebral infaction. 1988. Ref Type: Unpublished Work."},{"key":"10.1016\/j.blre.2007.11.001_bib40","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1159\/000100105","volume":"23","author":"Diener","year":"2007","journal-title":"Cerebrovasc Dis"},{"key":"10.1016\/j.blre.2007.11.001_bib41","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/j.1365-2141.2005.05617.x","article-title":"Air travel and thrombosis","volume":"130","author":"Chee","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2007.11.001_bib42","first-page":"985","article-title":"[Thromboembolic syndrome from prolonged sitting and flights of long duration: experience of the Emergency Medical Service of the Paris Airports]","volume":"183","author":"Clerel","year":"1999","journal-title":"Bull Acad Natl Med"},{"key":"10.1016\/j.blre.2007.11.001_bib43","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1001\/archinte.163.22.2766","article-title":"Incidence of air travel-related pulmonary embolism at the Madrid-Barajas airport","volume":"163","author":"Perez-Rodriguez","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.blre.2007.11.001_bib44","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1056\/NEJMoa010378","article-title":"Severe pulmonary embolism associated with air travel","volume":"345","author":"Lapostolle","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2007.11.001_bib45","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1055\/s-0037-1612996","article-title":"Fatal pulmonary embolism immediately after transatlantic air travel to the United States: less than one in a million","volume":"87","author":"Kline","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2007.11.001_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/000331970205300101","article-title":"Venous thrombosis from air travel: the LONFLIT3 study\u2013prevention with aspirin vs low-molecular-weight heparin (LMWH) in high-risk subjects: a randomized trial","volume":"53","author":"Cesarone","year":"2002","journal-title":"Angiology"},{"key":"10.1016\/j.blre.2007.11.001_bib47","unstructured":"SIGN Guideline. Prophylaxis of Venous Thromboembolism. http:\/\/www.sign.ac.uk\/guidelines\/fulltext\/62\/section11.html. 2002. Ref Type: Report."},{"key":"10.1016\/j.blre.2007.11.001_bib48","unstructured":"BCSH. Risk of venous thrombosis and long distance travel (including air flights) Information for travelers. http:\/\/www.bcshguidelines.com\/pdf\/venousthromb_230505.pdf. 23-5-2005. Ref Type: Report."},{"key":"10.1016\/j.blre.2007.11.001_bib49","unstructured":"Scottish Executive Health Department. Advice on travel related deep vein thrombosis. http:\/\/www.sehd.scot.nhs.uk\/publications\/DVTAirTravel.pdf. 30-12-2001. Ref Type: Report."},{"key":"10.1016\/j.blre.2007.11.001_bib50","first-page":"172","article-title":"Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera","volume":"23","author":"Tartaglia","year":"1986","journal-title":"Semin Hematol"},{"key":"10.1016\/j.blre.2007.11.001_bib51","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2007.11.001_bib52","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/cncr.20405","article-title":"Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease","volume":"101","author":"Srkalovic","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2007.11.001_bib53","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1182\/blood-2002-09-2846","article-title":"Multicenter phase 2 trial of thalidomide in relapsed\/refractory multiple myeloma: adverse prognostic impact of advanced age","volume":"102","author":"Mileshkin","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2007.11.001_bib54","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2007.11.001_bib55","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.V98.2.492","article-title":"Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients","volume":"98","author":"Barlogie","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.blre.2007.11.001_bib56","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2003.03.139","article-title":"Thalidomide alone or with dexamethasone for previously untreated multiple myeloma","volume":"21","author":"Weber","year":"2003","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.blre.2007.11.001_bib57","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1182\/blood-2006-04-015909","article-title":"A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma","volume":"108","author":"Richardson","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2007.11.001_bib58","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.blre.2007.11.001_bib59","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2002.02.116","article-title":"Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma","volume":"20","author":"Rajkumar","year":"2002","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.blre.2007.11.001_bib60","first-page":"826","article-title":"First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma","volume":"89","author":"Cavo","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2007.11.001_bib61","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1046\/j.1365-2141.2003.04345.x","article-title":"Thalidomide and dexamethasone for resistant multiple myeloma","volume":"121","author":"Anagnostopoulos","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2007.11.001_bib62","doi-asserted-by":"crossref","unstructured":"Hussein M, Jakubowiak A, Bolejack V, Zonder J, Barlogie B. S0204: Melphalan (MEL)-Based Tandem Autotransplants (TAT) for Multiple Myeloma (MM) with Thalidomide\/Dexamethasone (TD) Induction and Thalidomide\/Prednisone (TP) Maintenance: A Phase II Trial of the Southwest Oncology Group. Blood 108, 3088. 2006. Ref Type: Abstract.","DOI":"10.1182\/blood.V108.11.3088.3088"},{"key":"10.1016\/j.blre.2007.11.001_bib63","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1046\/j.1365-2141.2003.04473.x","article-title":"Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma","volume":"122","author":"Kropff","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2007.11.001_bib64","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/sj.thj.6200326","article-title":"Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma","volume":"5","author":"Dimopoulos","year":"2004","journal-title":"Hematol J"},{"key":"10.1016\/j.blre.2007.11.001_bib65","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/sj.thj.6200150","article-title":"The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed\/refractory multiple myeloma","volume":"3","author":"Garcia-Sanz","year":"2002","journal-title":"Hematol J"},{"key":"10.1016\/j.blre.2007.11.001_bib66","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1365-2141.2005.05521.x","article-title":"Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma","volume":"129","author":"Kyriakou","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2007.11.001_bib67","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00277-004-0981-5","article-title":"Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study","volume":"84","author":"Hovenga","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2007.11.001_bib68","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1634\/theoncologist.12-1-99","article-title":"Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial, HEM01-21","volume":"12","author":"Suvannasankha","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.blre.2007.11.001_bib69","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2007.11.001_bib70","doi-asserted-by":"crossref","unstructured":"Facon T, Mary J, Hulin C, Bennoubker L. Randomized Clinical Trial Comparing Melphalan-Prednisone (MP), MP-Thalidomide (MP-THAL) and High-Dose Therapy Using Melphalan 100 MG\/M2 (MEL100) for Newly Diagnosed Myeloma Patients Aged 65-75 Years. Interim Analysis of the IFM 99-06 Trial on 350 Patients. Blood 104.[206a] 16-11-2004. Ref Type: Abstract.","DOI":"10.1182\/blood.V104.11.206.206"},{"key":"10.1016\/j.blre.2007.11.001_bib71","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Repoussis P, Terpos E, Kyrtsonis M. Primary Treatment with Pulsed Melphalan, Dexamethasone, Thalidomide (MDT) for Symptomatic Patients with Multiple Myeloma = 75 Years of Age. Blood 104.[414a] 2004. Ref Type: Abstract.","DOI":"10.1182\/blood.V104.11.1482.1482"},{"key":"10.1016\/j.blre.2007.11.001_bib72","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/annonc\/mdh026","article-title":"Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study","volume":"15","author":"Zervas","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2007.11.001_bib73","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1600-0609.2004.00349.x","article-title":"Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma","volume":"74","author":"Schutt","year":"2005","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2007.11.001_bib74","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.4065\/80.12.1568","article-title":"The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma","volume":"80","author":"Baz","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.blre.2007.11.001_bib75","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1182\/blood-2002-01-0335","article-title":"Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy","volume":"100","author":"Zangari","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2007.11.001_bib76","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Spencer A, Attal M, Prince M. Study of Lenalidomide lus Dexamethasone Versus Dexamethasone Alone in Relapsed or Refractory Multiple Myeloma (MM): Results of a Phase 3 Study (MM-010). Blood,[106] 6a. 2005. Ref Type: Abstract.","DOI":"10.1182\/blood.V106.11.6.6"},{"key":"10.1016\/j.blre.2007.11.001_bib77","doi-asserted-by":"crossref","unstructured":"Weber D, Chen C, Niesvizky M, Wang M. Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): Results of a North American phase III study (MM-009). Journal of Clinical Oncology 2006;24[18s]:7521. Ref Type: Abstract.","DOI":"10.1200\/jco.2006.24.18_suppl.7521"},{"key":"10.1016\/j.blre.2007.11.001_bib78","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1056\/NEJMc053530","article-title":"Lenalidomide and venous thrombosis in multiple myeloma","volume":"354","author":"Knight","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2007.11.001_bib79","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1182\/blood-2006-01-0154","article-title":"Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis","volume":"108","author":"Zonder","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2007.11.001_bib80","doi-asserted-by":"crossref","unstructured":"Richardson PG, Schlossman R, Munshi N and Avigan DA. Phase 1 Trial of Lenalidomide (REVLIMID\u00ae) with Bortezomib (VELCADE\u00ae) in Relapsed and Refractory Multiple Myeloma. Blood 106, 365a. 2005. Ref Type: Abstract.","DOI":"10.1182\/blood.V106.11.365.365"},{"key":"10.1016\/j.blre.2007.11.001_bib81","doi-asserted-by":"crossref","unstructured":"Baz R, Choueiri T, jawde R and McGowan B. Doxil (D), Vincristine (V), Reduced Frequency Dexamethasone (d) and Revlimid(R) (DVd-R) Results in a High Response Rate in Patients with Refractory Multiple Myeloma (RMM). Blood 106, 2559a. 2005. Ref Type: Abstract.","DOI":"10.1182\/blood.V106.11.2559.2559"},{"key":"10.1016\/j.blre.2007.11.001_bib82","doi-asserted-by":"crossref","unstructured":"Palumbo A, Falco P, Musto P, and Corradini P. Oral RevlimidR Plus Melphalan and Prednisone (R-MP) for Newly Diagnosed Multiple Myeloma. Blood 106, 785a. 2005. Ref Type: Abstract.","DOI":"10.1182\/blood.V106.11.785.785"},{"key":"10.1016\/j.blre.2007.11.001_bib83","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","article-title":"Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.blre.2007.11.001_bib84","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Jacobus S, Callander N, Fonseca R. A Randomized Phase III Trial of Lenalidomide Plus High-Dose Dexamethasone Versus Lenalidomide Plus Low-Dose Dexamethasone in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group. Blood 2006;799a:108. Ref Type: Abstract.","DOI":"10.1182\/blood.V108.11.799.799"},{"key":"10.1016\/j.blre.2007.11.001_bib85","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.4065\/80.12.1568","article-title":"The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma","volume":"80","author":"Baz","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.blre.2007.11.001_bib86","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJMoa053583","article-title":"Thalidomide and hematopoietic-cell transplantation for multiple myeloma","volume":"354","author":"Barlogie","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2007.11.001_bib87","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1038\/sj.leu.2403533","article-title":"Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy","volume":"18","author":"Minnema","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2007.11.001_bib88","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1365-2141.2004.05078.x","article-title":"Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation","volume":"126","author":"Zangari","year":"2004","journal-title":"Br J Haematol"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X07000707?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X07000707?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T22:10:12Z","timestamp":1588284612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X07000707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":88,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["S0268960X07000707"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2007.11.001","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}